Background
Lexmark International manufactured printer toner cartridges protected by patents on cartridge technology and the software interface between cartridge and printer. Lexmark sold cartridges through two programs: a “Regular” program at full price, and a “Return Program” at a discounted price with a condition that purchasers not refill or resell the cartridges. Impression Products bought used Lexmark cartridges — some from domestic Return Program purchasers, others imported from overseas where Lexmark had sold them — refilled them, and resold them in the U.S. as compatible third-party replacements.
Lexmark sued for patent infringement. Impression Products defended on patent exhaustion grounds: when Lexmark sold a cartridge, it argued, Lexmark exhausted its patent rights in that specific cartridge and could not assert patent infringement against downstream purchasers or refurbishers. The case required the Federal Circuit to address two distinct exhaustion questions: (1) whether a clearly communicated single-use restriction at the time of domestic sale prevents exhaustion, and (2) whether Lexmark’s overseas sales exhausted its U.S. patent rights for those cartridges imported into the U.S.
The Court’s Holding
The en banc court, by a 10-2 majority, reaffirmed two longstanding Federal Circuit precedents. On domestic sales with restrictions, the court held that Lexmark’s clearly communicated Return Program restriction prevented exhaustion as to those cartridges: a patent holder who sells with an express restriction does not impliedly grant buyers the right to do what was expressly prohibited. The cartridge buyer received a limited license, not a fully exhausting sale. On foreign sales, the court held that U.S. patent rights are not exhausted by foreign sales — the first sale must occur in the U.S. under a U.S. patent to exhaust U.S. patent rights. Overseas sales by the patent holder are simply irrelevant to U.S. patent exhaustion.
The dissent by Judge Dyk, joined by Judge Hughes, argued that both holdings were inconsistent with Supreme Court patent and copyright exhaustion precedents and that the majority was entrenching a special patent law exception to general property principles that favor free alienability.
Key Takeaways
- Under the Federal Circuit’s 2016 holding, a clearly communicated restriction at the time of domestic sale could prevent patent exhaustion — giving patent holders control over downstream use through patent law even after sale.
- Foreign sales of patented goods by U.S. patent holders did not exhaust U.S. patent rights under the Federal Circuit’s holding, allowing patent holders to maintain parallel pricing and distribution control in different countries.
- The Supreme Court reversed both holdings in Impression Products v. Lexmark International (2017), holding that any authorized sale — domestic or foreign — exhausts U.S. patent rights, period, regardless of restrictions.
- The aftermath of the Supreme Court’s 2017 reversal had major implications for pharmaceutical parallel imports, printer consumables, auto parts, and any industry where patent holders sought to use patents to segment geographic markets or control downstream use.
Why It Matters
The Lexmark-Impression Products dispute is a landmark in the history of patent exhaustion doctrine, and the Federal Circuit’s 2016 en banc decision set up the Supreme Court’s most significant patent exhaustion ruling in decades. The questions at stake — can a patent holder use patent law to enforce resale restrictions after selling a product? Can foreign sales be insulated from U.S. patent exhaustion? — have enormous practical consequences across industries.
For the printer consumables market specifically, the case directly affected the aftermarket for toner and ink cartridges — a multi-billion-dollar industry where OEM manufacturers and third-party refillers compete. For pharmaceuticals, it determined whether drugmakers could sell drugs abroad at lower prices without enabling parallel imports into the U.S. The Supreme Court’s resolution in 2017 resolved these questions in favor of broad exhaustion, reshaping supply chains and pricing strategies across global product markets.